| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05532163 2022-001820-14 Details | 2024-04-17 Interventional | 4 | 1 | Natalizumab Multiple Sclero… Multiple Sclero… Sclerosis | Sponsor's decision - | |||
| NCT05422794 Details | 2024-04-17 Interventional | 1 | - | Albumin-Bound P… Paclitaxel Pembrolizumab Breast Neoplasm… Carcinoma Triple Negative… Anatomic Stage … Anatomic Stage … Locally Advance… Metastatic Trip… Unresectable Tr… | Other - DLT evaluation and analysis. - | |||
| NCT05355350 Details | 2024-04-17 Interventional | 4 | - | Meropenem Piperacillin Piperacillin, T… Tazobactam Bacteremia Bacterial Infec… Communicable Di… Enterobacteriac… Infections Beta Lactam Res… | No eligible patients found. Pending further center recruitment - | |||
| NCT05268926 2021-004073-31 Details | 2024-04-17 Interventional | 2 | 9 | Dapagliflozin Albuminuria Hypertension | Due to a delayed start-up and delayed patient inclusion in combination with new available
scientific data, continuation of the clinical study no longer serves a scientific purpose. - | |||
| NCT05120960 Details | 2024-04-17 Interventional | 1 | 0 | Osimertinib Tepotinib Brain Neoplasms Brain Tumor | 0 participant accrual - | |||
| NCT04032704 Details | 2024-04-17 Interventional | 2 | 205 | Pembrolizumab SGN-LIV1A Adenocarcinoma Carcinoma Carcinoma, Non-… Carcinoma, Squa… Esophageal Squa… Lung Neoplasms Small Cell Lung… Squamous Cell C… Gastric Adenoca… Gastroesophagea… Head and Neck S… Melanoma Non-small Cell … Non-small Cell … Prostate Cancer Small Cell Lung… | Study closed due to portfolio prioritization - | |||
| NCT03601507 Details | 2024-04-17 Interventional | 2 | 9 | Phosphoinositid… Carcinoma Carcinoma, Squa… Squamous Cell C… CDKN2A-p16 Posi… HPV Positive Or… Stage I Orophar… Stage II Oropha… Stage III Oroph… Stage IVA Oroph… | Novartis has chosen to withdraw support for this trial This study stopped accrual early as the investigational product (IP) manufacturer, Novartis, terminated the study stopping provision of IP. 6 out of 20 subjects were accrued, 5 of which completed study. Due to early termination with few patients, only the counts of events have been calculated and no testing was done. | |||
| NCT02233829 Details | 2024-04-17 Interventional | 1 | - | Dopamine Cocaine-Related… Cocaine Abuse | FDA Clinical and IRB Administrative Holds - | |||
| NCT01512888 Details | 2024-04-17 Interventional | 1/2 | - | Busulfan Immunologic Def… Severe Combined… X-Linked Combin… Severe Combined… | voluntary hold - | |||
| NCT06029530 Details | 2024-04-16 Interventional | 1 | 0 | Atropine Myopia | sIRB determined feasibility study could not be done because of no benefits of the treatment
drops in short time violated FDA requirements - | |||
| NCT05134194 Details | 2024-04-16 Interventional | 3 | 1 | Capecitabine Gemcitabine Vinorelbine Breast Neoplasm… Triple Negative… Triple Negative… | Sponsor R & D Strategy Adjustment] - | |||
| NCT04990388 2021-000903-19 Details | 2024-04-16 Interventional | 1/2 | 9 | Acetaminophen Antipyretics Cetirizine Famotidine Ibuprofen Disease Glycogen Storag… Glycogen Storag… | Sponsor decision not related to safety concerns - | |||
| NCT04376827 2018-003155-38 Details | 2024-04-16 Interventional | 2 | 33 | Antibodies, Mon… Lupus Nephritis Nephritis | Due to enrollment challenges, J&J Innovative Medicine decided to stop screening and terminate
the study early. This decision was not based on a safety concern. Due to enrollment challenges, the Sponsor decided to stop screening of new participants and stop the study early. Since a small number of participants only entered the LTE phase than the planned enrollment count, some of the planned safety analyses were not performed for the LTE phase participants. | |||
| NCT04151706 Details | 2024-04-16 Interventional | 2 | - | Busulfan Cyclophosphamid… Fludarabine Thiotepa Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Precursor Cell … Preleukemia Acute Leukemia Acute Lymphobla… Acute Myeloid L… Chronic Myeloid… | Interim analysis - | |||
| NCT03952585 Details | 2024-04-16 Interventional | 2/3 | - | Cisplatin Deoxyglucose Fluorodeoxygluc… Nivolumab Carcinoma Carcinoma, Squa… Oropharyngeal N… Squamous Cell C… Basaloid Squamo… Clinical Stage … Clinical Stage … Oropharyngeal S… Papillary Squam… Pathologic Stag… Pathologic Stag… Squamous Cell C… | End of Initial Phase of Multi-phase protocol - | |||
| NCT03604991 Details | 2024-04-16 Interventional | 2/3 | - | Albumin-Bound P… Carboplatin Ipilimumab Nivolumab Paclitaxel Adenocarcinoma Esophageal Neop… Clinical Stage … Clinical Stage … Clinical Stage … Clinical Stage … Clinical Stage … Clinical Stage … Esophageal Aden… Gastroesophagea… | End of Initial Phase of Multi-phase protocol - | |||
| NCT03558724 Details | 2024-04-16 Interventional | 1 | 25 | Bevacizumab Esophageal Neop… Esophageal Canc… | Dose-escalation was finished, but no clear correlation between fluorescence and tumor grade was
established - | |||
| NCT03201939 Details | 2024-04-16 Interventional | 2 | - | Lisinopril Acquired Immuno… Albuminuria Genetic Predisp… HIV Infections Kidney Diseases Genetic Predisp… HIV/AIDS | DSMB recommendations--lab QC issues relate to urine albumin measurement (>2-year pause). DSMB
approval obtained (3/24/2023) to re-open but will not enroll participants until new/separate
funding obtained as this award ends in Feb. 2024. - | |||
| NCT03029351 Details | 2024-04-16 Interventional | 4 | 15 | Exenatide Albuminuria Diabetes Mellit… Diabetes Mellit… Kidney Diseases Type2 Diabetes | termination by sponsor - | |||
| NCT01896999 Details | 2024-04-16 Interventional | 1/2 | - | Antibodies Antibodies, Mon… Antineoplastic … Brentuximab Ved… Immunoconjugate… Immunoglobulins Ipilimumab Nivolumab Hodgkin Disease Lymphoma Recurrent Class… Refractory Clas… | Other - Results of adult patient cohort released - |